Analgesic and Antidiarrheal Properties of Lappaconitine, Possibly Through Cyclooxygenase and µ‐Opioid Receptor Interaction Pathways: In Vivo and In Silico Studies | Synapse
February 25, 2026Immunity Inflammation and Disease0 citationsOpen Access
Analgesic and Antidiarrheal Properties of Lappaconitine, Possibly Through Cyclooxygenase and µ‐Opioid Receptor Interaction Pathways: In Vivo and In Silico Studies
The research aims to investigate the analgesic and antidiarrheal effects of lappaconitine and its interaction with cyclooxygenase and mu-opioid receptors.
Conducted in vivo studies to assess pain relief and diarrhea reduction effects of lappaconitine.
Performed in silico analyses to explore molecular interactions with cyclooxygenase and mu-opioid receptors.
Examined synergistic effects with diclofenac sodium and loperamide.
Lappaconitine showed significant analgesic properties in tested models.
It effectively reduced diarrhea symptoms.
Synergistic interactions with diclofenac sodium and loperamide were observed, enhancing overall efficacy.
Resumen
Therefore, LAP exerts potential analgesic and antidiarrheal effects, as well as synergistic properties with diclofenac sodium and loperamide through the cyclooxygenase and MOR interaction pathways.